


41272



*2-107-5-d*  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GILBERT V. LEVIN

Group Art Unit: 1623

Serial No.: 09/811,654

Filed: March 20, 2001

For: USE OF TAGATOSE IN PROMOTING  
CARDIOVASCULAR HEALTH

RECEIVED

MAY 16 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant brings the attached disclosures to the Examiner's attention and requests that they be considered and made of record in this application. Also attached is a completed PTO-1449 form.

Additionally, Applicant invites attention to the last two sentences on page 1 of the specification, viz:

"A pilot study was conducted at the University of Maryland to investigate the long term effects of D-tagatose in humans with type-2 diabetes. During the course of this study, there was found to be an increase in HDL-cholesterol levels in each of the subjects, both the patients and the controls, treated with the tagatose."

Respectfully submitted,

*Robert H. Berdo*

Robert H. Berdo  
Reg. No. 19,415  
Attorney for Applicant

Roylance, Abrams, Berdo & Goodman, L.L.P.  
1300 19<sup>th</sup> Street, N.W., Suite 600  
Washington, D.C. 20036-1649  
(202) 659-9076

Dated: May 15, 2001